Compare WOR & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOR | LQDA |
|---|---|---|
| Founded | 1955 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.1B |
| IPO Year | N/A | 2018 |
| Metric | WOR | LQDA |
|---|---|---|
| Price | $52.74 | $40.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $59.67 | $38.60 |
| AVG Volume (30 Days) | 137.4K | ★ 2.1M |
| Earning Date | 12-16-2025 | 11-03-2025 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | ★ 150.90 | N/A |
| EPS | ★ 2.13 | N/A |
| Revenue | ★ $1,253,567,000.00 | $69,216,000.00 |
| Revenue This Year | $17.70 | $1,005.03 |
| Revenue Next Year | $5.30 | $204.13 |
| P/E Ratio | $24.90 | ★ N/A |
| Revenue Growth | 7.43 | ★ 343.41 |
| 52 Week Low | $39.05 | $11.26 |
| 52 Week High | $70.91 | $42.46 |
| Indicator | WOR | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 66.89 |
| Support Level | $52.28 | $36.28 |
| Resistance Level | $54.29 | $42.46 |
| Average True Range (ATR) | 1.27 | 3.29 |
| MACD | 0.13 | 0.51 |
| Stochastic Oscillator | 54.63 | 88.07 |
Worthington Enterprises Inc is a designer and manufacturer of products and services, including manufactured metal products. The company operates under two reportable operating segments: Consumer Products and Building Products. The consumer Products business has a diverse product offering in the tools, outdoor living and celebrations categories, including propane-filled cylinders for torches, handheld torches, specialized hand tools, drywall tools, accessories and gas grills, and others. And the Building Products business engaged in providing pressurized containment solutions, providing critical components in the residential, non-residential, and repair and remodel end markets through essential categories. The company derives majority of the revenue from Building Products segment.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.